EXTH-22. TARGETING A NEWLY DISCOVERED IMMUNE CHECKPOINT, SIGLEC-15, INCREASES ONCOLYTIC EFFICACY OF ZIKA VIRUS (ZIKV) IN GLIOBLASTOMA (GBM)

作者
Ashwani Kesarwani,Sachendra S. Bais,Sharmila Nair,Amanda De Andrade Costa,Tong Hu,Pei‐Yong Shi,Michael S. Diamond,Milan G. Chheda
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:24 (Supplement_7): vii214-vii214
标识
DOI:10.1093/neuonc/noac209.821
摘要

Abstract We are developing ZIKV as a therapy for GBM. We previously demonstrated ZIKV specifically kills GBM stem cells. Using GL261 and CT2A mouse models, ZIKV induces a CD8+ T-cell mediated anti-tumor response and leads to 65% and 40% long term survivors, respectively (0%-untreated controls). ZIKV treatment significantly increases the number of myeloid cells in the tumor microenvironment (with about 10,000 infiltrating macrophages per ZIKV-treated brain, 1,000 cells per untreated brain). We hypothesized that by targeting a myeloid immune checkpoint, we would further enhance efficacy. Siglec-15 is a newly described myeloid checkpoint, and anti-siglec-15 antibody is currently in clinical trial for patients with advanced or metastatic solid tumors (NCT03665285). While there was no effect of anti-siglec-15 treatment alone, we observed increased efficacy when combined with ZIKV (cure rate: GL261-70%, CT2A-60% with ZIKV+anti-siglec-15 antibody; GL261-20%, CT2A-0% with anti-siglec-15 antibody alone; GL261-30%, CT2A-25% ZIKV alone; GL261-0%, CT2A-0% without treatment). Since recurrence is a major problem, we performed re-challenge experiments in cured mice at 6 months. Mice previously treated with anti-siglec-15 antibody and ZIKV had 70% long-term survival, compared to 30% of age matched untreated controls. This supports our earlier findings that an immunological response after ZIKV engenders long-term, tumor-specific, immune surveillance. Lastly, we used Siglec-15 knockout mice to confirm our observations. After treating Siglec-15 knockout mice bearing CT2A tumors with ZIKV, 70% animals were cured. There was no significant difference in survival between CT2A-bearing Siglec-15 knockout mice without ZIKV treatment compared to CT2A-bearing wild type hosts. Taken together, our work suggests targeting putative myeloid suppressor cells, combined with oncolytic ZIKV and its ensuing anti-cancer stem cell and activated CD8+ T-cell effects, may be an effective tool in neuro-oncology. Targeting Siglec-15 may also enhance other oncolytic or cytotoxic therapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
涨誊完成签到,获得积分20
1秒前
AN发布了新的文献求助10
2秒前
阿申爱乐的应助被dalong采纳,获得40
2秒前
深情安青的应助被三分之二采纳,获得10
3秒前
yunlong完成签到 ,获得积分10
4秒前
4秒前
4秒前
西陆发布了新的文献求助10
5秒前
WilliamTT发布了新的文献求助10
5秒前
东方天奇完成签到 ,获得积分10
5秒前
6秒前
syvshc的应助被RuYi采纳,获得10
6秒前
7秒前
慕青的应助被阿耒采纳,获得10
7秒前
7秒前
SchoLar完成签到 ,获得积分10
7秒前
慕青的应助被脑子大聪明采纳,获得10
7秒前
8秒前
8秒前
8秒前
9秒前
TCA关注了科研通微信公众号
9秒前
9秒前
科研通AI65的应助被小白采纳,获得10
9秒前
寻找布冯发布了新的文献求助10
10秒前
1111111完成签到,获得积分10
10秒前
10秒前
10秒前
lele发布了新的文献求助10
10秒前
fantasy的应助被和道一文字采纳,获得10
11秒前
动听千山发布了新的文献求助10
11秒前
玉米侠发布了新的文献求助10
12秒前
星燃发布了新的文献求助10
12秒前
Cuzz关注了科研通微信公众号
13秒前
13秒前
拼搏可冥发布了新的文献求助10
14秒前
Artsy发布了新的文献求助10
15秒前
Jasper的应助被三分之二采纳,获得10
15秒前
15秒前
cc发布了新的文献求助20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034